Eliem Therapeutics, Inc. (ELYM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Eliem Therapeutics, Inc. (ELYM) trades at $5.11. Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neuronal excitability disorders. Market cap: $343M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ELYM: ELYM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ELYM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ELYM: 2/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Eliem Therapeutics, Inc. (ELYM) Healthcare & Pipeline Overview
Eliem Therapeutics, Inc. is a clinical-stage biotechnology firm developing therapies for neuronal excitability disorders, including chronic pain and epilepsy. With Phase II clinical trials underway for ETX-810 and Phase I for ETX-155, Eliem targets unmet needs in central and peripheral nervous system disorders, positioning itself within a competitive biotech landscape.
What Is the Investment Thesis for ELYM?
Eliem Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on neuronal excitability disorders addresses a significant unmet medical need, with potential for substantial market growth. Key value drivers include the successful completion of clinical trials for ETX-810 and ETX-155, leading to potential FDA approval and commercialization. The company's market capitalization is $0.34 billion, and its negative P/E ratio of -7.89 reflects its current pre-revenue status. Upcoming clinical trial results will be critical catalysts. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and competition from other biotechnology and pharmaceutical companies. The company's beta of -0.38 suggests a low correlation with the overall market.
Based on FMP financials and quantitative analysis
ELYM Key Highlights
Eliem Therapeutics is a clinical-stage biotechnology company focused on neuronal excitability disorders.
- Lead drug candidate ETX-810 is in Phase IIa clinical trial for chronic pain.
- ETX-155 is in Phase I clinical trial for major depressive disorder, perimenopausal depression, and focal onset seizures.
- The company has preclinical programs targeting Kv7 for pain, epilepsy, and depression, and an Anxiolytic program for generalized anxiety disorder.
- Market Cap of $343M reflects investor valuation of pipeline potential.
Who Are ELYM's Competitors?
ELYM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CKPT Checkpoint Therapeutics, Inc. | $4.26 | +0.00% | $368M | 43 |
| GTHX G1 Therapeutics, Inc. | $7.16 | +0.14% | $378M | 64 |
| INZY Inozyme Pharma, Inc. | $4.00 | +0.25% | $258M | 44 |
| ITOS Iteos Therapeutics, Inc. | $10.15 | +0.20% | $449M | 64 |
| ORTX Orchard Therapeutics plc | $16.70 | +0.30% | $380M | 69 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ELYM's Key Strengths?
Promising pipeline of drug candidates targeting neuronal excitability disorders.
- Focus on unmet medical needs in large and growing markets.
- Experienced management team with expertise in drug development.
- Strong intellectual property position.
What Are ELYM's Weaknesses?
Clinical-stage company with no currently approved products.
- Dependence on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
- High risk of clinical trial failure.
What Could Drive ELYM Stock Higher?
ELYM catalyst: Phase IIa clinical trial results for ETX-810 in chronic pain (timeline dependent on trial progress).
- Phase I clinical trial data release for ETX-155 in major depressive disorder, perimenopausal depression, and focal onset seizures (timeline dependent on trial progress).
- Advancement of preclinical programs, including Kv7 Program and Anxiolytic program.
- Potential for strategic partnerships or collaborations to accelerate drug development.
What Are the Key Risks for ELYM?
Negative return on equity (-31.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for ETX-810 or ETX-155.
- Regulatory delays or rejection of drug candidates by the FDA.
- Competition from other companies developing therapies for neuronal excitability disorders.
- Dependence on securing additional funding to support research and development activities.
- Patent challenges or loss of intellectual property protection.
What Are the Growth Opportunities for ELYM?
- Advancement of ETX-810 in Chronic Pain: ETX-810, currently in Phase IIa clinical trials for chronic pain, represents a significant growth opportunity. The chronic pain market is substantial, with a global market size estimated at billions of dollars. Successful completion of Phase II and Phase III trials, followed by FDA approval, could lead to significant revenue generation for Eliem. The timeline for potential commercialization is dependent on trial outcomes, but could be within the next 3-5 years. Eliem's competitive advantage lies in the novel mechanism of action of ETX-810.
- Development of ETX-155 for Neuropsychiatric Disorders: ETX-155, currently in Phase I clinical trials for major depressive disorder, perimenopausal depression, and focal onset seizures, offers another substantial growth opportunity. The market for neuropsychiatric disorder treatments is large and growing, driven by increasing awareness and diagnosis of these conditions. Successful clinical development and regulatory approval could lead to a significant market share for Eliem. The timeline for potential commercialization is longer, potentially 5-7 years, given the early stage of development. Eliem's competitive advantage lies in targeting specific unmet needs within these disorders.
- Expansion of Kv7 Program: Eliem's preclinical Kv7 program, targeting pain, epilepsy, and depression, represents a longer-term growth opportunity. The Kv7 channel is a validated target for these conditions, and Eliem's program has the potential to develop novel therapies with improved efficacy and safety profiles. The timeline for potential commercialization is longer, potentially 7-10 years, given the preclinical stage of development. The market size for these indications is substantial, offering significant revenue potential.
- Anxiolytic Program for Generalized Anxiety Disorder: Eliem's preclinical anxiolytic program targeting generalized anxiety disorder (GAD) presents a growth opportunity in a market with significant unmet needs. GAD affects a large population, and new, more effective treatments are needed. Successful development and commercialization of this program could provide Eliem with a strong position in the anxiety disorder market. The timeline for potential commercialization is long-term, requiring several years of preclinical and clinical development.
- Strategic Partnerships and Acquisitions: Eliem has the opportunity to grow through strategic partnerships and acquisitions. Partnering with larger pharmaceutical companies could provide access to additional funding, resources, and expertise to accelerate the development and commercialization of its drug candidates. Acquiring other biotechnology companies with complementary technologies or pipelines could expand Eliem's portfolio and market reach. The timing and success of these opportunities are uncertain, but they represent a potential avenue for growth.
What Are ELYM's Competitive Advantages?
- Proprietary drug candidates targeting specific neuronal excitability pathways.
- Intellectual property protection through patents and exclusivity.
- Clinical trial data demonstrating efficacy and safety of drug candidates.
What Does ELYM Do?
Eliem Therapeutics, Inc., founded in 2018 and headquartered in Redmond, Washington, is a clinical-stage biotechnology company dedicated to the development of novel therapies for neuronal excitability disorders. These disorders encompass a range of conditions affecting the central and peripheral nervous systems, including chronic pain, neuropsychiatric disorders, epilepsy, and other neurological conditions. The company's mission is to address significant unmet medical needs in these areas by developing innovative treatments that can improve the lives of patients suffering from these debilitating conditions. Eliem's pipeline includes two lead drug candidates in clinical development. ETX-810 is being developed for the treatment of chronic pain and is currently in a Phase IIa clinical trial. ETX-155 is being investigated for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures and is in Phase I clinical trials. In addition to these clinical-stage programs, Eliem has several preclinical programs in development, including a Kv7 Program targeting pain, epilepsy, and depression, and an Anxiolytic program for the treatment of generalized anxiety disorder. These programs reflect Eliem's commitment to developing a broad portfolio of therapies for neuronal excitability disorders. Eliem Therapeutics operates in the highly competitive biotechnology industry, facing competition from both established pharmaceutical companies and other emerging biotechnology firms. The company's success depends on its ability to successfully develop and commercialize its drug candidates, navigate the regulatory approval process, and secure adequate funding to support its research and development activities. With a focused approach and a pipeline of promising drug candidates, Eliem Therapeutics aims to become a leading player in the treatment of neuronal excitability disorders.
What Products and Services Does ELYM Offer?
- Develop therapies for neuronal excitability disorders.
- Focus on chronic pain, neuropsychiatry, epilepsy, and other CNS disorders.
- Advance ETX-810, a drug candidate for chronic pain, through Phase IIa clinical trials.
- Develop ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures in Phase I clinical trials.
- Conduct preclinical research on Kv7 Program for pain, epilepsy, and depression.
- Develop an Anxiolytic program for the treatment of generalized anxiety disorder.
How Does ELYM Make Money?
- Develop and license or commercialize novel therapeutics.
- Focus on addressing unmet needs in neuronal excitability disorders.
- Generate revenue through potential future sales of approved drugs or licensing agreements.
What Industry Does ELYM Operate In?
Eliem Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The industry is driven by the increasing demand for novel therapies to treat a wide range of diseases and conditions. The market for treatments targeting neuronal excitability disorders is substantial, driven by the prevalence of chronic pain, neuropsychiatric disorders, and epilepsy. Eliem competes with other biotechnology and pharmaceutical companies developing therapies in these areas. The industry is subject to stringent regulatory requirements, with the FDA playing a critical role in the approval and commercialization of new drugs. The biotechnology industry is experiencing growth, fueled by advances in genomics, proteomics, and other areas of scientific research.
Who Are ELYM's Key Customers?
- Patients suffering from chronic pain.
- Patients with major depressive disorder, perimenopausal depression, and focal onset seizures.
- Potential pharmaceutical partners for licensing or co-development agreements.
Insider Activity
The most recent 11 insider filings for Eliem Therapeutics, Inc. break down as 8 sales and 3 purchases. On net that is roughly 374K shares acquired (about $1.5M) — insiders putting money in tends to read as conviction.
ELYM Valuation & Market Position
With a $343M market cap, Eliem Therapeutics, Inc. sits in the small-cap segment of the market.
Key Financial Metrics
Return on equity for Eliem Therapeutics, Inc. stands at -31.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 27.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Eliem Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 29.49 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Eliem Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.69.
Company Profile
Eliem Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redmond, US. The company is led by CEO Aoife M. Brennan BAO, BCh, MB, MMSc. ELYM has traded publicly since 2021.
ELYM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Eliem's pipeline focuses on neurological disorders, a high-need area where successful drugs can command premium pricing. Think Biogen's Alzheimer's drug, but with potentially fewer side effects if Eliem's approach works.
- Recent insider buying suggests those in the know see value, even if the broader market hasn't caught on yet. It's like when Musk bought more Tesla shares during a dip - confidence booster.
- The community seems hopeful about upcoming trial data, a potential catalyst. Positive results could drastically shift market perception, similar to how Sarepta's DMD drug data moved their stock.
- Eliem's approach to treating chronic pain could be a game-changer if successful, considering the opioid crisis and the need for non-addictive alternatives.
Bear Case
- Neurological drug development is notoriously risky; high failure rates are the norm. It's like betting on a biotech startup - potential for huge reward, but also total loss.
- Community sentiment, while hopeful, is also cautious, reflecting past disappointments in the sector. Remember the hype around certain COVID treatments that ultimately fizzled?
- The company's cash runway could be a concern if trials take longer or cost more than expected. Dilution can quickly erode shareholder value, like what happened with numerous small-cap biotechs during the 2022 downturn.
- The market perception of small-cap biotechs is generally negative right now, making it harder for Eliem to gain traction. It's swimming against the tide, similar to how renewable energy companies struggled during periods of low oil prices.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ELYM Latest News
No recent news available for ELYM.
ELYM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ELYM.
Price Targets
Wall Street price target analysis for ELYM.
ELYM MoonshotScore
What does this score mean?
The MoonshotScore rates ELYM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Aoife M. Brennan BAO, BCh, MB, MMSc
Chief Executive Officer
Aoife M. Brennan is the Chief Executive Officer of Eliem Therapeutics. She holds a BAO, BCh, MB from Trinity College Dublin, and an MMSc from Harvard Medical School. Dr. Brennan has extensive experience in the biotechnology industry, having held leadership positions at various companies. Her background includes expertise in drug development, clinical research, and medical affairs. Her experience spans across multiple therapeutic areas, including neurology and psychiatry, aligning with Eliem's focus.
Track Record: Since joining Eliem Therapeutics, Dr. Brennan has overseen the advancement of the company's pipeline, including the progression of ETX-810 and ETX-155 through clinical trials. She has also been instrumental in securing funding and building a strong team. Her leadership is focused on driving the company's mission to develop innovative therapies for neuronal excitability disorders.
What Investors Ask About Eliem Therapeutics, Inc. (ELYM) — Healthcare
What does Eliem Therapeutics, Inc. do?
Eliem Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders. These disorders encompass a range of conditions affecting the central and peripheral nervous systems, including chronic pain, neuropsychiatric disorders, epilepsy, and other neurological conditions.
What are the main risks for ELYM?
As a clinical-stage biotechnology company, Eliem Therapeutics faces several key risks. The most significant risk is the potential failure of its drug candidates in clinical trials. Clinical trial failures can result in significant financial losses and a decline in the company's stock price.
How does Eliem Therapeutics, Inc. navigate regulatory approval processes?
Eliem Therapeutics navigates regulatory approval processes primarily through adherence to FDA guidelines and regulations. This involves meticulous planning and execution of clinical trials, ensuring data integrity, and maintaining open communication with regulatory agencies.
How does Eliem Therapeutics, Inc. manage patent expiration risks?
As a clinical-stage biotechnology company, Eliem Therapeutics manages patent expiration risks through a multi-faceted approach. This includes actively seeking patent protection for its drug candidates, formulations, and methods of use. The company also focuses on developing new generations of its therapies with novel intellectual property to extend market exclusivity.
What are the key factors to evaluate for ELYM?
Evaluate ELYM on fundamentals, analyst consensus, and risk factors. Eliem Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does ELYM data refresh on this page?
ELYM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ELYM's recent stock price performance?
Eliem Therapeutics, Inc. (ELYM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising pipeline of drug candidates targeting neuronal excitability disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ELYM overvalued or undervalued right now?
Eliem Therapeutics, Inc. (ELYM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.